Aerie Pharmaceuticals Inc. (Nasdaq: AERI) reported positive results from a Phase 3 trial of Rhopressa to treat glaucoma sending the stock price soaring $12.35 to $30.35.
Positive trial results for Aerie Pharmaceuticals
September 19, 2015 at 01:47 AM EDT
